| 摘要 |
A compound of formula (I) wherein R<1a>, R<1b>, R<3a> and R<3b> independently represent hydrogen or C1-C4 alkyl; R<2a> and R<2b> independently represents hydrogen, C1-C4 alkyl or CH2CN; A<1> represents O, S or NR<4a>; B<1> represents O, S or NR<4b>; R<4a> represents hydrogen, C1-C4 alkyl, C2-C4 alkenyl; or together R<3a> and R<4a> form a ring; R<4b> represents hydrogen, C1-C4 alkyl, C2-C4 alkenyl; or together R<3b> and R<4b> form a ring; A<2> and B<2> independently represent C(O), C(NH), OC(O), NHC(O), NHC(S), SO2, or a bond; Z represents (CH2)n Y(CH2)m; n and m are independently 0-4; Y represents O, S, NR<5>, CHR<6>, Ar, or Ccy; Ccy represents a 5-10 membered carbocycle including cyclopentane and adamantane; Ar represents phenyl, naphthyl; or a 5- or 6- membered heterocyclic ring containing zero to four nitrogens, zero to one sulfurs and zero to one oxygens; Ar is optionally substituted with one or more substituents selected from: hydrogen, halogen, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, CN, NO2, CF3, OR<7>, NR<8>R<9>, and COOR<10>; R<7>, R<8> and R<9> are independently hydrogen, C1-C4 alkyl, aryl, heteroaryl, C(O)R<11>, C(O)R<12>, SO2R<13>, or; R<8> and R<9> together may be (CH2)j Q(CH2)k, where Q is O, S, NR<14> or a bond; j is 2-4; k is 0-2; R<5>, R<6>, R<10>, R<11>, R<12>, R<13> and R<14> are independently hydrogen, C1-4 alkyl, aryl or heteroaryl; or an enantiomer thereof, and pharmaceutically acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, especially for treatment of conditions associated with reductions in nicotinic transmission. The compounds of the invention enhance the efficacy of agonists at nicotinic receptors.
|
